Dr. Hafron highlights the most significant prostate cancer treatment advances in 2022
In this interview, Jason M. Hafron, MD, recaps the biggest advances in the prostate cancer treatment paradigm in 2022. Hafron is a partner at the Michigan Institute of Urology, PC; an associate professor of Urology at the William Beaumont School of Medicine, Oakland University; and the director of Robotic Surgery at Beaumont Hospital Royal Oak in Michigan.
Hafron J. Dr. Hafron highlights the most significant prostate cancer treatment advances in 2022. Urology Times 2022 Dec 13:https://www.urologytimes.com/view/dr-hafron-highlights-the-most-significant-prostate-cancer-treatment-advances-in-2022